Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

NCT02144038 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed and Refractory Multiple Myeloma

Interventions

DRUG: LGH447
DRUG: BYL719

Sponsor

Novartis Pharmaceuticals